key: cord-0692602-i10zvurg
authors: Oladunni, Fatai S.; Park, Jun-Gyu; Chiem, Kevin; Ye, Chengjin; Pipenbrink, Michael; Walter, Mark R.; Kobie, James; Martinez-Sobrido, Luis
title: Selection, Identification, and Characterization of SARS-CoV-2 Monoclonal Antibody Resistant Mutants
date: 2021-01-26
journal: J Virol Methods
DOI: 10.1016/j.jviromet.2021.114084
sha: 2ca96523445fe5249a0c48f97cba499fb2b3157a
doc_id: 692602
cord_uid: i10zvurg

The use of monoclonal neutralizing antibodies (mNAbs) is being actively pursued as a viable intervention for the treatment of Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) infection and associated coronavirus disease 2019 (COVID-19). While highly potent mNAbs have great therapeutic potential, the ability of the virus to mutate and escape recognition and neutralization of mNAbs represents a potential problem in their use for the therapeutic management of SARS-CoV-2. Studies investigating natural or mNAb-induced antigenic variability in the receptor binding domain (RBD) of SARS-CoV-2 Spike (S) glycoprotein, and their effects on viral fitness, are still rudimentary. In this manuscript we described experimental approaches for the selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants (MARMs) in cultured cells. The ability to study SARS-CoV-2 antigenic drift under selective immune pressure by mNAbs is important for the optimal implementation of mNAbs for the therapeutic management of COVID-19. This will help to identify essential amino acid residues in the viral S glycoprotein required for mNAb-mediated inhibition of viral infection, to predict potential natural drift variants that could emerge upon implementation of therapeutic mNAbs, as well as vaccine prophylactic treatments for SARS-CoV-2 infection, and to assess MARM viral fitness and potential to induce severe infection and associated COVID-19 disease.

The rapid emergence of a novel coronavirus, which was later named Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2), in December 2019 has led to a major public health threat needing an immediate therapeutic breakthrough. While the process involved in vaccine development might take more than a year before becoming commercially available, the use of monoclonal neutralizing antibodies (mNAbs) or plasma from recovered patients become an important part of the conversation to quickly control coronavirus disease 2019 (COVID-19) and COVID-19-associated illnesses.

Neutralizing antibodies (NAbs) are essential part of the host adaptive immune response that are induced against viral infections following natural infection or administration of vaccine (1) . A prerequisite for a successful SARS-CoV-2 infection is the interaction between the heterotrimeric Spike (S) glycoprotein and its functional receptor, the angiotensin converting enzyme 2 (ACE2), found on susceptible host cells (2) . The receptor-binding domain (RBD) of SARS-CoV-2 S protein is important for this entry J o u r n a l P r e -p r o o f process, and has been identified as a dominant target of many of the currently identified SARS-CoV-2 mNAbs (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . During viral entry, SARS-CoV-2 S protein is cleaved at the S1/S2 cleavage site ( Figure 1A ) by host cell proteases into S1, containing the RBD, and the S2 subunit, which is responsible for the conformational changes that mediates fusion of the viral membrane with the host cell endosome (19) . While the receptor binding motif, a sequence within the RBD, dictates the binding activity of SARS-CoV-2 S and also contributes to infectivity (20) , mutations within key residues of the SARS-CoV-2 S which facilitates S1/S2 cleavage may also enhance infectivity (19) .

The main target of mNAbs against SARS-CoV-2 are the epitopes on the S (11).

While some SARS-CoV-2-induced Abs can preferentially bind to either the S1 or S2 subunit of the S protein, others can bind, with a high affinity, to the RBD located within the S1 subunit (21, 22) . A major draw-back for the development of potent antivirals or immunotherapies against RNA viruses is the rapid development of resistant mutants (18, 23) . Being an RNA virus, SARS-CoV-2 is under constant pressure to mutate and evade neutralization of mNAbs (18, 23) . It has been reported that a significant proportion of COVID-19 patients induced a low level of NAbs (3) which might have resulted from the inability of natural infection to induce robust B-cell expansion and affinity maturation in such individuals (3, 17, 24) . Constant (17) . Here we describe in detail molecular approaches to select J o u r n a l P r e -p r o o f 14 . Formalin solution, neutral buffered, 10% (Sigma-Aldrich, catalog # HT501128). 15 . Triton X-100, 0.5% (Sigma-Aldrich, catalog # X100-500ML). 16 . Human monoclonal antibody (hmAb) 1212C2 (produced in house) (25) guidelines. As such, manipulation of SARS-CoV-2 should follow biosafety precautions and only be carried out in a biosafety level 3 (BSL3) facility with strict adherence to the relevant institutional biosafety committee (IBC) guidelines. Extra care must be taken not to generate aerosols and droplets when handling SARS-CoV-2 samples in a BSL3 containment. All researchers handling SARS-CoV-2 must take proper biosafety training to work in a BSL3 facility and be cleared to carry out procedures requiring working with the virus. All cell culture procedures in this protocol were carried out in BSL2. All work involving SARS-CoV-2 was performed at BSL3 facilities. Proper inactivation procedures of infected plates required full submersion in 10% formalin solution for 24 h before moving infected plates to a BSL2 laboratory for further processing. Texas Biomedical Research Institute's IBC approved all protocols. For all experiments, we seeded cells the day before infection to achieve approximately ~85-95% confluency. We recommend using fresh Vero E6 cells, between passage 1-10 J o u r n a l P r e -p r o o f as we have found that these cells grow better, and are more viable at low passage. It is also important to maintain healthy cells free of any contaminant, including mycoplasma.

For the experiments in this manuscript we used SARS-CoV-2 isolate USA-WA1/2020 obtained from BEI Resources (26) (27) (28) (29) . We recommend using a multiplicity of 

A key factor in the infectivity of SARS-CoV-2 is the ability of the S glycoprotein ( Figure 1A) to bind with high affinity to its receptor, ACE2, to initiate virus infection (33) . 13. Harvest the TCS from Px and freeze down at -80°C until further use.

Before sequencing SARS-CoV-2 MARMs, it is important to first validate the resistance of the generated MARMs to the mNAb (Figure 4) . Our group (27) 

In order to validate the resistance of the generated MARMs for binding of the mNAb, we recommend to use IFA in Vero E6 cells infected with MARM SARS-CoV-2. We recommend to use mock-infected cells as well as cells infected with WT SARS-CoV-2 as internal controls (Figure 5) . Likewise, we recommend to use the isotype control and an antibody able to recognize both, the WT and MARM SARS-CoV-2, as internal controls in the IFA (Figure 5 ). 18. Analyze the samples under a fluorescence microscope.

To determine if the identified SARS-CoV-2 MARM has similar viral fitness than SARS-CoV-2 WT, we compare the growth kinetics and the plaque phenotype of SARS- ix. Stop the reaction by removing the developing solution, and wash with 1 mL/well of PBS.

x. Take pictures of the plaque phenotypes using a scanner (Figure 6B ).

To identify the amino acid(s) residue(s) that play a critical role in the antigenic drift of SARS-CoV-2 under immune pressure induced by the presence of the mNAb, it is important to sequence of the MARM and compare it to that of the WT SARS-CoV-2.

can also help in mapping out the epitope(s) that are critical for binding of the mNAb.

Sequence analyses of different SARS-CoV-2 isolates have suggested that the RBD is a highly variable region that is subject to selective pressure by antibody immune responses (35) . Amino acid substitutions within the RBD have played a major role in the ability of coronaviruses to overcome the species barrier, initially allowing animal-tohuman transmission and subsequent adaptation to transmission among humans (36) .

Similarly, functional mutations in the RBD and the N-terminal domain of SARS-CoV-2 S glycoprotein that conferred immune resistance to mNAbs or convalescent plasma have been reported (17) . Importantly, sequence information of these variant pathotypes can help identify amino acid residues that enabled immune evasion and viral fitness. (Figure 3) . On the other hand, in all the viral passages, SARS-CoV-2 was able to induce CPE even in the highest concentration of the isotype control mAb (Figure 3) , similar to the well with no mAb (Figure 2 , blue).

Our data showed that the MARM generated after serial passage of SARS-CoV-2 now replicates in the presence of the mNAb in both the pre-and post-treatment setting conditions, similar to the control well with no mNAb (Figure 4) . This is an indicator that the virus has now undergone mutation(s) on its epitope binding site enabling it to escape the neutralizing effect of the mNAb. This is in contrast to the parental virus J o u r n a l P r e -p r o o f (SARS-CoV-2 WT) which was efficiently neutralized by the same mNAb in both pre-and pos-treatment conditions (Figure 4) .

Similarly, the loss of binding activity of the mNAb was also interrogated by IFA ( Figure 5 ). As expected, the mNAb lost its binding affinity to SARS-CoV-2 MARMinfected Vero E6 cells (Figure 5) . On the other hand, SARS-CoV-2 WT was recognized by the mNAb. Both, cells infected with SARS-CoV-2 WT and MARM were similarly recognized by the 3B4E10 mAb control, while the isotype control mAb was not able to recognize SARS-CoV-2 WT or MARM infected cells ( Figure 5) . None of the Abs (mNAb, 3B4E10, or isotype control) were able to detect SARS-CoV-2 S in mockinfected cells ( Figure 5) . Altogether, the PRMNT (Figure 4 ) and the IFA ( 

Vero E6 cells (American Type Culture Collection, ATCC; catalog # CRL-1586)

SARS-CoV-2 isolate USA-WA1/2020 (BEI Resources, catalog # NR-52281)

Dulbecco's modified Eagle medium, DMEM (Corning, catalog # 15-013-CV)

Penicillin-Streptomycin L-glutamine 100X, PSG (Corning, catalog # 30-009-CI)

Fetal bovine serum, FBS (Avantor Seradigm, catalog # 1500-500)

2% (Oxoid, catalog # LP0028)

Bovine serum albumin, 35% (BSA; Sigma-Aldrich, catalog # A7409)

DMEM/F-12 powder (Gibco, catalog # 12400-024)

Cell culture grade water (Corning, catalog # 25-055-CV)

Sodium bicarbonate, 5% (Sigma, catalog # S-5761)

Correlates of protection induced by vaccination

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Human neutralizing antibodies elicited by SARS-CoV-2 infection

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual

Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike

Neutralizing Antibodies from COVID-19 Patients

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

A human monoclonal antibody blocking SARS-CoV-2 infection

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Genetic diversity and evolution of SARS-CoV-2

Serological Analysis of New York City COVID19 Convalescent Plasma Donors

2020. herapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters

Generation of Recombinant SARS-CoV-2 Using a Bacterial Artificial Chromosome

Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome

Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice

Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Inhibition of SARS-CoV-2 by type I and type III interferons

Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)

An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening

Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus

Adaptive evolution of the spike gene of SARS coronavirus: changes in positively selected sites in different epidemic groups

Distinct repertoire of antigenic variants of foot-and-mouth disease virus in the presence or absence of immune selection

Hepatitis A virus mutant spectra under the selective pressure of monoclonal antibodies: codon usage constraints limit capsid variability

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Author Correction: Virological assessment of hospitalized patients with COVID-2019

CoV-2 induced similar CPE with all the concentrations of the isotype control mAb independent of the virus passage. Scale bars

Figure 4

Virus neutralization was quantified using ELISPOT, and the percentage of infectivity calculated using sigmoidal dose response curve. Mock-infected cells (No virus) and cells infected with MARM or WT SARS-CoV-2 in the absence of mNAb (No mNAb) were included as internal controls